Docta Complutense
Publicación
Artículo científico (JournalArticle)
Pharmacological evaluation of non-nucleotide purine derivatives as P2X7 antagonists for the treatment of neuroinflammation in traumatic brain injury
Background and purpose: Traumatic brain injury (TBI) is considered to be a leadingcause of mortality and disability worldwide. After TBI, innate immunity is rapidly acti-vated in response to damage-associated molecular patterns, such as ATP release,recognised by P2X7 receptors. The P2X7-NLRP3 inflammasome axis has been identi-fied as one of the main players in neuroinflammation. This study aimed to validateP2X7 receptors as therapeutic target for traumatic brain injury.
Experimental approach: P2X7 receptors were studied by genetic and pharmacologi-cal approaches. Six non-nucleotide purine derivatives were evaluated as P2X7 antag-onists. Compounds that prevented LPS + ATP-induced IL-1β release from primaryglial cultures were investigated in the closed-head injury TBI model in vivo in malemice. Finally, we evaluated soluble (s)P2X7 receptor plasmatic levels in a cohort ofTBI patients.
Key results: P2rx7 / mice showed an exaggerated inflammatory response 24 hpost-TBI compared to control mice. However, animals treated with the selective P2X7 antagonist JNJ-47965567 (30 mg kg 1 i.p.) 30 min post-TBI showed improvedneurological and inflammatory parameters. The purine derivative ITH15004 was themost potent compound reducing IL-1β production in vitro. When administered in vivo30 min post-TBI, ITH15004 (1 mg kg 1 i.p.) improved both neuro-behavioural andinflammatory markers at 24 h. In TBI patients, we showed a tendency towardsincrease in circulating sP2X7 receptor levels at 24 and 72 h post-TBI.
Conclusions and implications: These results highlight the importance of P2X7 recep-tors in the acute phase of TBI and present ITH15004 as a promising pharmacologicaltool to counteract P2X7 receptor-dependent neuroinflammation in vivo.
Proyecto:
Instituto de Salud Carlos III / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI19/00082
,
Instituto de Salud Carlos III / Plan Estatal de Investigación Científica PI22/00362
,
Agencia Estatal de Investigación / Técnica y de Innovación 2021-2023 PID2022-140164OB-C21
,
European Commission / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 766124